MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rpth.2025.103334

Медицинская библиотека · Research and practice in thrombosis and haemostasis · 2025

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.

Timmerije Rick, Schols Saskia E M, Meijer Daniëlle, Barteling Wideke, Stroobants An K, Rijpma Sanna R

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Direct oral anticoagulants (DOACs) interfere with clot-based assays, including factor (F)VIII testing and the Nijmegen-Bethesda assay, potentially leading to false-positive results for FVIII inhibitors. Misinterpretation of these results carries serious clinical consequences. Activated charcoal-based products, such as DOAC Remove, may restore assay accuracy, but data supporting their use in FVIII inhibitor assays are limited.

OBJECTIVES

In this study, we aim to determine DOAC interference in FVIII inhibitor testing and evaluate effectivity of DOAC removal to restore assay reliability.

METHODS

Normal pooled plasma was spiked with therapeutic and supratherapeutic concentrations of apixaban, edoxaban, rivaroxaban, and dabigatran. Plasma pools from persons with acquired hemophilia A were spiked with DOACs and retested with and without DOAC removal treatment to evaluate workflow performance. FVIII inhibitor activity was measured with and without activated charcoal-based DOAC removal to establish DOAC interference and removal efficacy.

RESULTS

Spiking experiments with DOACs caused concentration-dependent false-positive FVIII inhibitor results (>0.6 Nijmegen Bethesda Units/mL), with dabigatran showing the strongest interference and apixaban the weakest. DOAC removal substantially reduced or eliminated interference across all drugs. Post-removal FVIII inhibitor values closely matched baseline concentrations in both spiked normal pooled plasma and pooled patient plasma, with most results within ±20% of the assay variability.

CONCLUSION

DOACs significantly interfere with FVIII inhibitor assays, potentially causing clinically significant false-positive results. Activated charcoal-based DOAC removal treatment provides a practical solution to restore assay reliability. These findings support the integration of DOAC removal into anti-FVIII testing protocols for patients on anticoagulant therapy.

Для цитирования: Timmerije Rick, Schols Saskia E M, Meijer Daniëlle, Barteling Wideke, Stroobants An K, Rijpma Sanna R. Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.. Research and practice in thrombosis and haemostasis. 2025. DOI: 10.1016/j.rpth.2025.103334.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.